Presentations and Publications

13-04-2022
I Maser, C Hartl, T Michels, R Milde, V Klein, M Maraslis, P Beckhove, N Khandelwal, M Yule, H Loferer and S Bissinger
OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to cell death and eradicates immune-checkpoint resistant tumors synergistically in combination with PD-1 inhibition
22-06-2020
T Michels, S Bissinger, P Sennhenn, H Loferer, C Martins Freire, O Reidell, S Meier-Ewert, A Papadimitriou, P Beckhove and N Khandelwal
A first-in-class SIK3 inhibitor, OMX-0370, effectively inhibits tumor growth in syngeneic tumor models, as single agent, by abolishing tumor resistance to immune-derived TNF
26-09-2019
T Michels, A Sorrentino, AN Menevse, S Bissinger, P Sennhenn, V Volpin, S Genssler, H Loferer, C Kohler, R Spang, M Rheli, C Schmidl, M Breinig, M Boutros, S Meier-Ewert, A Papadimitriou, P Beckhove and N Khandelwal
Salt-inducible kinase 3 facilitates tumor cell resistance against cytotoxic T cell attack by shifting TNF signaling from apoptosis to survival
26-09-2019
M Aigner, S Genssler, A Rathinasamy, S Urlinger, J Zantow, S Bissinger, T Michels, S Braendle, R Milde, J Regula, A Papadimitriou, P Beckhove and N Khandelwal
Inhibition of novel immune-checkpoint IGSF11 mediates efficient tumor cell killing in vitro and in vivo